Blueprint Medicines Corporation (BPMC): The stock had negative money flow to the tune of ($0.82 million) on Wednesday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $0.52 million, whereas, the outflow of money on downticks was $1.34 million and the ratio between the two was 0.39. The block trade had a negative net money flow of ($1.04 million). On the other hand, downticks amounted to $1.04 million of the traded value, which shows distribution in the stock by traders. Blueprint Medicines Corporation (BPMC) closed with marginal gains of 78 cents to end the day at $28.5, an increase of 2.81% over the previous days close. The stock recorded -0.35% for the week.
Blueprint Medicines Corporation has dropped 2.26% in the last five trading days, however, the shares have posted positive gains of 1.68% in the last 4 weeks. Blueprint Medicines Corporation is up 49.58% in the last 3-month period. Year-to-Date the stock performance stands at 8.24%.
Blueprint Medicines Corporation (BPMC) : The consensus on Blueprint Medicines Corporation (BPMC) based on 4 analyst recommendation on the company stock is 1.25, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future.
Blueprint Medicines Corporation (NASDAQ:BPMC): The stock opened at $27.7 and touched an intraday high of $28.61 on Wednesday. During the day, the stock corrected to an intraday low of $27.59, however, the bulls stepped in and pushed the price higher to close in the green at $28.51 with a gain of 2.85% for the day. The total traded volume for the day was 279,645. The stock had closed at $27.72 in the previous trading session.
Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V, active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Companys BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Companys Imatinib, which is an inhibitor of KIT and PDGFRa, is approved in SM and GIST. The Companys other drug candidate is BLU-554, which targets FGFR4, a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.